Answer
Spravato (esketamine hydrochloride) is not recommended during pregnancy or in women of childbearing potential not using contraception; if pregnancy occurs during treatment, treatment should be discontinued and counselling about potential foetal risks and clinical/therapeutic options provided as soon as possible.
Sources for this answer
- Spravato 28 mg nasal spray, solutionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 12Document updated
Sources checked